The effects of immunosuppression on regulatory CD4+CD25 + T cells: Impact on immunosuppression selection in transplantation

Molecular Diagnosis and Therapy

Volumn 12, Issue 3, 2008, Pages 171-181

  Javeed, Aqeel ^a,b   Zhao, Yong ^a,b  

^a INSTITUTE OF ZOOLOGY   (China)

^b China US Joint Research Center for Life Sciences   (China)

Author keywords

Immune function; Immunosuppressants, general; Immunosuppression; T cells; Transplant rejection; Transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CALCITRIOL; CAMPATH 1G; CD40 LIGAND MONOCLONAL ANTIBODY; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; LF 15 0195; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45RB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 4; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ASTHMA; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MIXED LYMPHOCYTE REACTION; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SHORT COURSE THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION; TREATMENT RESPONSE;

EID: 44449136111     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256281     Document Type: Review

References (124)

1. Nashan B. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors. Transplant Int 2004; 17: 279-85
2. Chan L, Gaston R, Hariharan S. Evolution of immunosuppression and continued importance of acute rejection in renal transplantation. Am J Kidney Dis 2001; 38 (6 Suppl. 6): S2-9
3. Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 2005; 80 (2 Suppl.): S221-34
4. Shapiro R, Young JB, Milford EL, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5: 874-86
5. Kirk AD. Induction immunosuppression. Transplantation 2006; 82: 593-602
6. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210
7. Cobbold SP, Adams E, Graca L, et al. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 2006; 213: 239-55
8. Aluvihare VR, Betz AG. The role of regulatory T cells in alloantigen tolerance. Immunol Rev 2006; 212: 330-43
9. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-11
10. Vigouroux S, Yvon E, Biagi E, et al. Antigen-induced regulatory T cells. Blood 2004; 104: 26-33
11. Wing K, Fehervari Z, Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells. Int Immunol 2006; 18: 991-1000
12. Steger U, Kingsley CI, Karim M, et al. CD25+CD4+ regulatory T cells develop in mice not only during spontaneous acceptance of liver allografts but also after acute allograft rejection. Transplantation 2006; 82: 1202-9
13. Setoguchi R, Hori S, Takahashi T, et al. Homeostatic maintenance of natural FOXP3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201: 723-35
14. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004; 172: 3983-8
15. Stephens LA, Gray D, Anderton SM. CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci U S A 2005; 102: 17418-23
16. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003; 171: 3348-52
17. Zhao Y. The two simultaneously occurring processes in one immune response: the positive immune reaction and immune tolerance. Med Hypotheses 2006; 67: 1384-5
18. Zhao Y. The different effects of cyclosporin A and rapamycin on regulatory CD4+CD25+T cells: potential relationship with transplant tolerance induction. Expert Rev Clin Immunol 2007; 3: 1-4
19. Sakaguchi S, Ono M, Setoguchi R, et al. FOXP3+ CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27
20. Sakaguchi S. Naturally arising FOXP3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52
21. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10: 1969-80
22. Cederbom L, Hall H, Ivars F. CD4+CD25+ regulatory T cells down-regulate costimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30: 1538-43
23. Chen D, Zhang N, Fu S, et al. CD4+ CD25+ regulatory T-cells inhibit the islet innate immune response and promote islet engraftment. Diabetes 2006; 55: 1011-21
24. Fontenot JD, Gavin MA, Rudensky AY. FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-6
25. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FOXP3. Science 2003; 299: 1057-61
26. Zhang L, Zhao Y. The regulation of FOXP3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol 2007; 211: 590-7
27. Kingsley CI, Karim M, Bushell AR, et al. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080-6
28. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-50
29. Dai Z, Li Q, Wang Y, et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 2004; 113: 310-7
30. Salama AD, Najafian N, Clarkson MR, et al. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1643-51
31. Masunaga T, Yamashita K, Sakihama H, et al. Dimeric but not monomeric soluble CD40 prolongs allograft survival and generates regulatory T cells that inhibit CTL function. Transplantation 2005; 80: 1614-22
32. Jiang S, Camara N, Lombardi G, et al. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 2003; 102: 2180-6
33. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 1641-6
34. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005; 105: 2220-6
35. Yi H, Zhen Y, Jiang L, et al. The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells. Cell Mol Immunol 2006; 3: 189-95
36. Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in FOXP3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-51
37. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+FOXP3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005; 6: 1152-9
38. Wang H, Zhao L, Sun Z, et al. A potential side effect of cyclosporin A: inhibition of CD4(+)CD25(+) regulatory T cells in mice. Transplantation 2006; 82: 1484-92
39. Shibutani S, Inoue F, Aramaki O, et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 2005; 79: 904-13
40. Gao W, Oukka M, Kuchroo V, et al. Contrasting effects of cyclosporin and rapamycin in de novo generation of alloantigen-stimulated regulatory T cells. Transplantation 2006; 82: 79
41. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101: 2886-93
42. Taylor PA, Lees CJ, Wilson JM, et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002; 100: 3400-7
43. Kawai M, Kitade H, Mathieu C, et al. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 2005; 79: 1073-7
44. Smith CR, Mohanakumar T, Shimizu Y, et al. Brief cyclosporine treatment prevents intrathymic (IT) tolerance induction and precipitates acute rejection in an IT rat cardiac allograft model. Transplantation 2000; 69: 294-9
45. Segundo DS, Ruiz JC, Izquierdo M, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006; 82: 550-7
46. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110-7
47. Strauss L, Whiteside TL, Knights A, et al. Selective survival of naturally occurring human CD4+CD25+FOXP3+ regulatory T cells cultured with rapamycin. J Immunol 2007; 178: 320-9
48. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FOXP3+ regulatory T cells. Blood 2005; 105: 4743-8
49. Keever-Taylor CA, Browning MB, Johnson BD, et al. Rapamycin enriches for CD4(+) CD25(+) CD27(+) FOXP3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 2007; 9: 144-57
50. Coenen JJ, Koenen HJ, van Rijssen E, et al. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107: 1018-23
51. Valmori D, Tosello V, Souleimanian NE, et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006; 177: 944-9
52. Qu Y, Zhang B, Zhao L, et al. The effect of immunosuppressive drug rapamycin on regulatory CD4(+)CD25(+)FOXP3(+)T cells in mice. Transpl Immunol 2007; 17: 153-61
53. Tian L, Lu L, Yuan Z, et al. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery. Transplantation 2004; 77: 183-9
54. Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338-47
55. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55: 40-9
56. Bensinger SJ, Walsh PT, Zhang J, et al. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 2004; 172: 5287-96
57. Suarez A, Lopez P, Gomez J, et al. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006; 65: 1512-7
58. Fattorossi A, Battaglia A, Buzzonetti A, et al. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 2005; 116: 134-41
59. Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114: 1425-33
60. Navarro J, Aristimuno C, Sanchez-Ramon S, et al. Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy. J Neuroimmunol 2006; 176: 153-61
61. Chen X, Oppenheim JJ, Winkler-Pickett RT, et al. Glucocorticoid amplifies IL-2-dependent expansion of functional FOXP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006; 36: 2139-49
62. Chen X, Murakami T, Oppenheim JJ, et al. Differential response of murine CD4+CD25+ and CD4+CD25-T cells to dexamethasone-induced cell death. Eur J Immunol 2004; 34: 859-69
63. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195: 603-16
64. Fiorucci S, Antonelli E, Distrutti E, et al. NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A 2002; 99: 15770-5
65. Rea D, van Kooten C, van Meijgaarden KE, et al. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 2000; 95: 3162-7
66. Pedersen AE, Gad M, Walter MR, et al. Induction of regulatory dendritic cells by dexamethasone and 1alpha,25-Dihydroxyvitamin D(3). Immunol Lett 2004; 91: 63-9
67. Stock P, Akbari O, De Kruyff RH, et al. Respiratory tolerance is inhibited by the administration of corticosteroids. J Immunol 2005; 175: 7380-7
68. Gregori S, Casorati M, Amuchastegui S, et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167: 1945-53
69. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460-8
70. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256-62
71. Hale DA, Gottschalk R, Maki T, et al. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation 1998; 65: 473-9
72. Minamimura K, Gao W, Maki T. CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 2006; 176: 4125-32
73. Ogawa N, Minamimura K, Kodaka T, et al. Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes. J Autoimmun 2006; 26: 225-31
74. Hale DA, Gottschalk R, Umemura A, et al. Immunologic mechanisms in tolerance produced in mice with nonradiation-based lymphoablation and donor-specific bone marrow. Transplantation 2002; 74: 477-84
75. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+FOXP3+ regulatory T cells. J Am Soc Nephrol 2006; 17: 2844-53
76. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161-5
77. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients: CHIB 201 International Study Group. Lancet 1997; 350: 1193-8
78. Vincenti F, de Andres A, Becker T, et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int 2006; 19: 446-57
79. McNeill A, Spittle E, Backstrom BT. Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61. Scand J Immunol 2007; 65: 63-9
80. Kohm AP, McMahon JS, Podojil JR, et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 2006; 176: 3301-5
81. Li W, Carper K, Liang Y, et al. Anti-CD25 mAb administration prevents spontaneous liver transplant tolerance. Transplant Proc 2006; 38: 3207-8
82. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823-32
83. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006; 105: 430-7
84. Imai H, Saio M, Nonaka K, et al. Depletion of CD4(+)CD25(+) regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007; 98: 416-23
85. Game DS, Hernandez-Fuentes MP, Lechler RI. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 2005; 5: 454-64
86. Kreijveld E, Koenen HJ, Klasen IS, et al. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007; 7: 249-55
87. Luke PP, O'Brien CA, Jevnikar AM, et al. Anti-CD45RB monoclonal antibody-mediated transplantation tolerance. Curr Mol Med 2001; 1: 533-43
88. Salvalaggio PR, Camirand G, Ariyan CE, et al. Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo. J Immunol 2006; 176: 2292-8
89. Basadonna GP, Auersvald L, Khuong CQ, et al. Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci U S A 1998; 95: 3821-6
90. Luke PP, Deng JP, Lian D, et al. Prolongation of allograft survival by administration of anti-CD45RB monoclonal antibody is due to alteration of CD45RBhi: CD45RBlo T-cell proportions. Am J Transplant 2006; 6: 2023-34
91. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003; 170: 1304-12
92. Chen G, Luke PP, Yang H, et al. Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. Am J Transplant 2007; 7: 27-37
93. Winsor-Hines D, Merrill C, O'Mahony M, et al. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol 2004; 173: 4715-23
94. Hall BM, Fava L, Chen J, et al. Anti-CD4 monoclonal antibody-induced tolerance to MHC-incompatible cardiac allografts maintained by CD4+ suppressor T cells that are not dependent upon IL-4. J Immunol 1998; 161: 5147-56
95. Aramaki O, Shirasugi N, Akiyama Y, et al. Induction of operational tolerance and generation of regulatory cells after intratracheal delivery of alloantigen combined with nondepleting anti-CD4 monoclonal antibody. Transplantation 2003; 76: 1305-14
96. Saitovitch D, Bushell A, Mabbs DW, et al. Kinetics of induction of transplantation tolerance with a nondepleting anti-Cd4 monoclonal antibody and donor-specific transfusion before transplantation: a critical period of time is required for development of immunological unresponsiveness. Transplantation 1996; 61: 1642-7
97. Sawitzki B, Kingsley CI, Oliveira V, et al. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005; 201: 1925-35
98. Cobbold SP, Castejon R, Adams E, et al. Induction of FOXP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172: 6003-10
99. Karim M, Kingsley CI, Bushell AR, et al. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004; 172: 923-8
100. Yi H, Zhao Y. The enhanced percentages of Treg cells in depleting anti-CD4 mAb-treated mice. Transplantation. In press
101. Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 2002; 20: 215-29
102. Lockwood CM, Hale G, Waldman H, et al. Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003; 42: 1539-44
103. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006; 19: 705-14
104. Knechtle SJ, Pirsch JD, Fechner JH, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-30
105. Masuyama J, Kaga S, Kano S, et al. A novel costimulation pathway via the 4C8 antigen for the induction of CD4+ regulatory T cells. J Immunol 2002; 169: 3710-6
106. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006; 120: 247-59
107. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465-74
108. Nathan MJ, Yin D, Eichwald EJ, et al. The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells. Am J Transplant 2002; 2: 323-32
109. Zheng XX, Sanchez-Fueyo A, Domenig C, et al. The balance of deletion and regulation in allograft tolerance. Immunol Rev 2003; 196: 75-84
110. Uchida N, Shirasugi N, Akiyama Y, et al. Induction of indefinite survival of fully allogeneic cardiac grafts and generation of regulatory cells by intratracheal delivery of alloantigens under blockade of the CD40 pathway. Transplantation 2003; 75: 878-84
111. Ito H, Takeuchi Y, Shaffer J, et al. Anti-CD40L monoclonal antibodies can replace anti-CD4 monoclonal antibodies for the nonmyeloablative induction of mixed xenogeneic chimerism. Transplantation 2006; 82: 251-7
112. Coenen JJ, Koenen HJ, van Rijssen E, et al. Tolerizing effects of co-stimulation blockade rest on functional dominance of CD4+CD25+ regulatory T cells. Transplantation 2005; 79: 147-56
113. Bisikirska BC, Herold KC. Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes. Ann N Y Acad Sci 2004; 1037: 1-9
114. Herold KC, Taylor L. Treatment of type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation? Immunol Res 2003; 28: 141-50
115. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158: 2947-54
116. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9: 1202-8
117. Bisikirska B, Colgan J, Luban J, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005; 115: 2904-13
118. Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004; 172: 1691-8
119. Valzasina B, Guiducci C, Dislich H, et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005; 105: 2845-51
120. Ito T, Wang YH, Duramad O, et al. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci U S A 2006; 103: 13138-43
121. Kreijveld E, Koenen HJ, Hilbrands LB, et al. The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+CD25- T cells. Blood 2007 Jan 1; 109 (1): 244-52
122. Lamioni A, Parisi F, Isacchi G, et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005; 79: 846-50
123. Grimbert P, Bouguermouh S, Baba N, et al. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J Immunol 2006; 177: 3534-41
124. Zhang A, Qu Y, Zhang B, et al. The different effects of indirubin on effector and CD4+CD25+ regulatory T cells in mice: potential implication for the treatment of autoimmune diseases. J Mol Med 2007; 85: 1263-70